143 related articles for article (PubMed ID: 28041971)
1. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
Rossi ED; Bizzarro T; Monterossi G; Inzani F; Fanfani F; Scambia G; Zannoni GF
Hum Pathol; 2017 Apr; 62():99-107. PubMed ID: 28041971
[TBL] [Abstract][Full Text] [Related]
2. How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
Thomakos N; Dimopoulou S; Sotiropoulou M; Machairiotis N; Pandraklakis A; Haidopoulos D; Liontos M; Bamias A; Rodolakis A
Horm Mol Biol Clin Investig; 2020 Dec; 42(1):105-111. PubMed ID: 33781006
[TBL] [Abstract][Full Text] [Related]
3. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract][Full Text] [Related]
4. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
6. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.
Soslow RA; Bissonnette JP; Wilton A; Ferguson SE; Alektiar KM; Duska LR; Oliva E
Am J Surg Pathol; 2007 Jul; 31(7):979-87. PubMed ID: 17592263
[TBL] [Abstract][Full Text] [Related]
8. Molecular Profiles of Mixed Endometrial Carcinoma.
Matrai C; Motanagh S; Mirabelli S; Ma L; He B; Chapman-Davis E; Kurtis B; Elemento O; Mosquera JM; Ellenson LH
Am J Surg Pathol; 2020 Aug; 44(8):1104-1111. PubMed ID: 32604171
[TBL] [Abstract][Full Text] [Related]
9. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
[TBL] [Abstract][Full Text] [Related]
10. The impact of lymph vascular space invasion on recurrence and survival in patients with early stage endometrial cancer.
Loizzi V; Cormio G; Lorusso M; Latorre D; Falagario M; Demitri P; Scardigno D; Selvaggi LE
Eur J Cancer Care (Engl); 2014 May; 23(3):380-4. PubMed ID: 24112088
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
12. Effects of surgical volumes on the survival of endometrial carcinoma.
Becker JH; Ezendam NP; Boll D; van der Aa M; Pijnenborg JM
Gynecol Oncol; 2015 Nov; 139(2):306-11. PubMed ID: 26348315
[No Abstract] [Full Text] [Related]
13. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
Han G; Soslow RA; Wethington S; Levine DA; Bogomolniy F; Clement PB; Köbel M; Gilks B; DeLair D
Int J Gynecol Pathol; 2015 Jul; 34(4):323-33. PubMed ID: 25851704
[TBL] [Abstract][Full Text] [Related]
14. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
15. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
16. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
[TBL] [Abstract][Full Text] [Related]
17. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
18. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
19. Bcl-2 expression and prognosis of patients with endometrial carcinoma.
Sakuragi N; Ohkouchi T; Hareyama H; Ikeda K; Watari H; Fujimoto T; Kuwabara M; Yamamoto R; Sagawa T; Fujino T; Fujimoto S
Int J Cancer; 1998 Apr; 79(2):153-8. PubMed ID: 9583730
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
